文献速递血栓与止血贫血与红细胞疾病白血病

JAK1/2抑制剂芦可替尼同情用药治疗重型COVID-19:一项前瞻性观察性研究

Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study.
PubMed 文献 · Leukemia · 2020-08-19

这项前瞻性观察性研究纳入34例重型COVID-19患者,在同情用药方案下接受芦可替尼治疗,中位年龄80.5岁,85.3%有≥2种合并症。第28天总生存率为94.1%,临床改善(序贯量表评分改善≥2分)的累积发生率为82.4%(95%CI 71-93),85.3%患者出院回家。作者结论认为芦可替尼在老年高危重型COVID-19患者中安全且与肺功能改善相关,但需对照临床试验确立疗效。

要点

  • 34例重型COVID-19患者接受芦可替尼同情用药,第28天总生存率94.1%。
  • 临床改善(序贯量表评分改善≥2分)累积发生率82.4%(95%CI 71-93)。
  • PaO2/FiO2<200 mmHg者临床改善较少见,低流量与高流量氧疗间无差异。

核心结论

  • 在老年且合并症多的重型COVID-19患者前瞻性队列中,同情用药芦可替尼安全,并与肺功能改善及85.3%患者出院回家相关。
  • 作者指出需开展对照临床试验以确立芦可替尼治疗COVID-19的疗效。

研究设计与样本

  • 前瞻性观察性研究,纳入34例在同情用药方案下接受芦可替尼治疗的COVID-19患者。
  • 重型肺部疾病定义为影像学示肺部浸润且空气下血氧饱和度≤93%和/或PaO2/FiO2≤300 mmHg。
  • 中位年龄80.5岁,85.3%有≥2种合并症;芦可替尼中位暴露时间13天,中位剂量强度20 mg/天。

主要发现

  • 第28天总生存率为94.1%。
  • 序贯量表评分改善≥2分的累积发生率为82.4%(95%CI 71-93)。
  • 临床改善不受低流量与高流量氧疗支持影响,但在PaO2/FiO2<200 mmHg患者中较少见。
  • 最常见不良事件为贫血、尿路感染和血小板减少。
  • 第14天观察到炎症细胞因子谱及活化淋巴细胞亚群改善。

临床怎么用

  • 作者结论认为在老年高危合并症重型COVID-19患者中同情用药芦可替尼安全,并与肺功能改善和出院回家相关,但需对照临床试验确立疗效。

局限性

  • 原文结论指出需开展对照临床试验以确立芦可替尼治疗COVID-19的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Overwhelming inflammatory reactions contribute to respiratory distress in patients with COVID-19. Ruxolitinib is a JAK1/JAK2 inhibitor with potent anti-inflammatory properties. We report on a prospective, observational study in 34 patients with COVID-19 who received ruxolitinib on a compassionate-use protocol. Patients had severe pulmonary disease defined by pulmonary infiltrates on imaging and an oxygen saturation ≤ 93% in air and/or PaO2/FiO2 ratio ≤ 300 mmHg. Median age was 80.5 years, and 85.3% had ≥ 2 comorbidities. Median exposure time to ruxolitinib was 13 days, median dose intensity was 20 mg/day. Overall survival by day 28 was 94.1%. Cumulative incidence of clinical improvement of ≥2 points in the ordinal scale was 82.4% (95% confidence interval, 71-93). Clinical improvement was not affected by low-flow versus high-flow oxygen support but was less frequent in patients with PaO2/FiO2 < 200 mmHg. The most frequent adverse events were anemia, urinary tract infections, and thrombocytopenia. Improvement of inflammatory cytokine profile and activated lymphocyte subsets was observed at day 14. In this prospective cohort of aged and high-risk comorbidity patients with severe COVID-19, compassionate-use ruxolitinib was safe and was associated with improvement of pulmonary function and discharge home in 85.3%. Controlled clinical trials are necessary to establish efficacy of ruxolitinib in COVID-19.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Vannucchi AM, Sordi B, Morettini A, et al. Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. Leukemia. 2020. PMID: 32814839. doi:10.1038/s41375-020-01018-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。